This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Datta, K. Articles by Mukhopadhyay, D. Search for Related Content PubMed PubMed Citation Articles by Datta, K. Articles by Mukhopadhyay, D.

The 104–123 Amino Acid Sequence of the ß-domain of von Hippel-Lindau Gene Product Is Sufficient to Inhibit Renal Tumor Growth and Invasion¹

Departments of Pathology [K. D., C. S., D. M.] and Medicine [S. A. K.], Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215

The von Hippel-Lindau (VHL) tumor suppressor gene is mutated in patients with VHL disease and in the majority of patients with sporadic renal cell carcinomas (RCCs). RCCs are dependent on insulin-like growth factor-I receptor-mediated signaling for tumor growth and invasion in vivo. Reintroduction of the VHL gene product (pVHL) can inhibit on insulin-like growth factor-I receptor-mediated signaling in RCC cells in vitro through interaction with protein kinase C and is mediated by a specific amino acid sequence (104–123) in the ß-domain of the pVHL. In the present study, the amino acid sequence (104–123) of the pVHL was conjugated to the protein transduction domain of HIV-TAT protein (TATFLAGVHL-peptide) to facilitate entry into cells, and we demonstrate that this amino acid region of VHL is sufficient to block proliferation and invasion of 786-O renal cancer cells in vitro. Furthermore, daily i.p. injections with the TATFLAGVHL peptide retarded and, in some cases, caused partial regression of renal tumors that were implanted in the dorsal flank of nude mice. Treatment with this peptide also inhibits the invasiveness of renal tumors. A 56% decrease in the proliferative index in tumors treated with the TATFLAGVHL-peptide versus control-peptide-treated mice was observed. Taken together, these results show the novel importance of a 20-amino acid sequence of the ß-domain of the VHL gene product capable of inhibiting tumor growth and invasion. These results lay the foundation for a unique approach toward treating RCCs using this small-molecular-weight peptide fused to the TAT-sequence, which may, in the future, be used alone or in conjunction with other therapies.

This article has been cited by other articles:

				K. L. Wu, H. Miao, and S. Khan JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1836 - F1846. [Abstract] [Full Text] [PDF]

				M. Noguchi, V. Ropars, C. Roumestand, and F. Suizu Proto-oncogene TCL1: more than just a coactivator for Akt FASEB J, August 1, 2007; 21(10): 2273 - 2284. [Abstract] [Full Text] [PDF]

				J. Zhou, J. Fan, and J.-T. Hsieh Inhibition of Mitogen-Elicited Signal Transduction and Growth in Prostate Cancer with a Small Peptide Derived from the Functional Domain of DOC-2/DAB2 Delivered by a Unique Vehicle. Cancer Res., September 15, 2006; 66(18): 8954 - 8958. [Abstract] [Full Text] [PDF]

				E. Nakamura, P. Abreu-e-Lima, Y. Awakura, T. Inoue, T. Kamoto, O. Ogawa, H. Kotani, T. Manabe, G.-J. Zhang, K. Kondo, et al. Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor Protein Am. J. Pathol., February 1, 2006; 168(2): 574 - 584. [Abstract] [Full Text] [PDF]

				M. Hiromura, F. Okada, T. Obata, D. Auguin, T. Shibata, C. Roumestand, and M. Noguchi Inhibition of Akt Kinase Activity by a Peptide Spanning the {beta}A Strand of the Proto-oncogene TCL1 J. Biol. Chem., December 17, 2004; 279(51): 53407 - 53418. [Abstract] [Full Text] [PDF]

				W. G. Kaelin Jr. The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6290S - 6295S. [Abstract] [Full Text] [PDF]

				L. Wang, H. Zeng, P. Wang, S. Soker, and D. Mukhopadhyay Neuropilin-1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor-dependent Endothelial Cell Migration J. Biol. Chem., December 5, 2003; 278(49): 48848 - 48860. [Abstract] [Full Text] [PDF]

				W. G. Kaelin Jr. The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2703 - 2711. [Abstract] [Full Text] [PDF]

				A. Fittipaldi, A. Ferrari, M. Zoppe, C. Arcangeli, V. Pellegrini, F. Beltram, and M. Giacca Cell Membrane Lipid Rafts Mediate Caveolar Endocytosis of HIV-1 Tat Fusion Proteins J. Biol. Chem., September 5, 2003; 278(36): 34141 - 34149. [Abstract] [Full Text] [PDF]

				H. Murata, N. Tajima, Y. Nagashima, M. Yao, M. Baba, M. Goto, S. Kawamoto, I. Yamamoto, K. Okuda, and H. Kanno Von Hippel-Lindau Tumor Suppressor Protein Transforms Human Neuroblastoma Cells into Functional Neuron-like Cells Cancer Res., December 1, 2002; 62(23): 7004 - 7011. [Abstract] [Full Text] [PDF]

				D. MUKHOPADHYAY and H. ZENG Involvement of G Proteins in Vascular Permeability Factor/ Vascular Endothelial Growth Factor Signaling Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 275 - 284. [Abstract] [PDF]